Clinical trials: IDDM
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Versus Insulin Detemir, Both Combined With Insulin Aspart in Subjects With Type 1 Diabetes
This trial is conducted in Japan. The aim of this clinical trial is to investigate the safety (with emphasis on hypoglycaemia) after switching from long-acting insulin analogue or intermediate-acting insulin to insulin degludec…
- Trial name
- NCT00841087
- Testing
- insulin degludec, insulin detemir, insulin aspart
- Where
- 8 sites in Japan
- Volunteers
- 65 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 1
Comparison of Basal (Fasting) Glycemic Control in Type 1 Diabetic Patients With CSII Achieved by the Circadian Slide Ruler Scale or Flat Basal Rate
This is a pilot trial to establish study procedures that allow comparison of various starting basal rate profiles used in Continuous Subcutaneous Insulin Infusion (CSII).
- Trial name
- NCT00569452
- Testing
- Accu-Chek Spirit Insulin Pump
- Where
- Germany
- Volunteers
- 12 people
- Sponsor
- Hoffmann-La Roche
Type 1 Diabetes, Diabetes Mellitus, Type 1
Safety and Efficacy of CELZ-201 in Patients With Recent Onset Type 1 Diabetes
The brief purpose of this research study is to learn about the safety and efficacy of intra-arterial administration of CELZ-201 in patients with newly diagnosed Type 1 Diabetes Mellitus (T1D).
- Trial name
- CREATE-1 (NCT05626712)
- Testing
- CELZ-201 Administration, Control Group
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Creative Medical Technology Holdings Inc
Type 1 Diabetes, Type 2 Diabetes
Closed Loop Glucose Control in a Simulated ICU Setting
This is a proof of concept safety study of a rule-based closed loop glucose control system designed for use in the intensive care unit setting.
- Conditions
- Type 1 Diabetes, Type 2 Diabetes, Stress Induced Hyperglycemia
- Trial name
- NCT07646067
- Testing
- FUSION closed loop glucose control system
- Volunteers
- 6 people
- Sponsor
- Ideal Medical Technologies
Diabetes Mellitus Type 1
Blood Glucose Control With BioChaperone Insulin Lispro Compared to Insulin Lispro (Humalog®) After Ingestion of a Standardized Meal
The addition of BioChaperone to already marketed prandial insulin analogue accelerates the onset and shorten the duration of action of insulin lispro due to facilitation of the absorption of the insulin after subcutaneous…
- Trial name
- NCT02344992
- Testing
- BioChaperone insulin lispro, Humalog®
- Where
- Germany
- Volunteers
- 38 people
- Sponsor
- Adocia
Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder (TI Inhalation Powder)When an Optimal Dose is Taken With Varied Carbohydrate Intake
The purpose of this study is to determine if, once a favorable dose of TI Inhalation Powder is established for either a type 1 or 2 patient, based on a average diabetic meal, the patient's favorable dose can be used safely…
- Trial name
- NCT00747006
- Testing
- TI Inhalation Powder and Humalog (Amendment 1), TI Inhalation Powder (original protocol)
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Mannkind Corporation
Diabetic Kidney Disease
Phase 2 Study of INV-202 in Patients With Diabetic Kidney Disease
The study is designed to assess the efficacy, safety, tolerability, and transformation within the human body of INV-202 investigational drug in the treatment of adult participants with a diagnosis of Diabetic Kidney Disease due…
- Trial name
- NCT05514548
- Testing
- INV-202
- Where
- 72 sites in United States, Canada and 5 more
- Volunteers
- 265 people
- Sponsor
- Inversago Pharma Inc.
Diabetes, Diabetes Mellitus, Type 1
Efficacy and Safety of Insulin Aspart in MDI or CSII in Children Below 7 Years of Age With Type 1 Diabetes
This trial is conducted in Europe. The aim of this trial is to investigate the efficacy of insulin aspart compared to soluble human insulin on blood glucose control in children below 7 years of age with type 1 diabetes.
- Trial name
- NCT00571935
- Testing
- insulin aspart, soluble human insulin
- Where
- 5 sites in Poland
- Volunteers
- 61 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)
The purpose of this non-interventional extension study is to continue to collect long-term safety and other clinical data for an additional 42 months in participants who completed the PROTECT study.
- Trial name
- NCT04598893
- Testing
- Teplizumab
- Where
- 47 sites in United States, Belgium and 6 more
- Volunteers
- 188 people
- Sponsor
- Provention Bio, a Sanofi Company
Hypoglycemia
Glucagon Ready-to-Use (RTU) for Prevention of Exercise-Induced Hypoglycemia During Aerobic Exercise in Adults With T1D
This study is a randomized, placebo-controlled, double-blind, 2-treatment, 2-period, crossover comparison in a clinical research center (CRC) setting, followed by a randomized, placebo-controlled, double-blinded, 2-arm parallel…
- Trial name
- NCT03841526
- Testing
- Glucagon RTU Injection With Insulin Pump Reduction, Vehicle for Glucagon RTU Injection With Insulin Pump Reduction, Glugaon RTU Injection Without Insulin Pump Reduction
- Where
- Canada
- Volunteers
- 48 people
- Sponsor
- Xeris Pharmaceuticals
Diabetes, Diabetes Mellitus, Type 1
Comparison of Insulin Degludec With Insulin Glargine in Subjects With Type 1 Diabetes Mellitus
This trial was conducted in Europe. The aim of this trial was to compare the pharmacodynamic (the effect of the investigated drug on the body) response of insulin degludec (insulin 454) with insulin glargine at steady-state…
- Trial name
- NCT01868529
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 63 people
- Sponsor
- Novo Nordisk A/S
Malignant Melanoma
Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma
This study was a mixed phase Ib/II, multi-center, open-label study of tebentafusp (IMCgp100) as a single agent, and in combination with durvalumab and/or tremelimumab, in metastatic cutaneous melanoma.
- Trial name
- NCT02535078
- Testing
- Tebentafusp (IMCgp100)
- Where
- 4 sites in United States
- Sponsor
- Immunocore Ltd
Type 1 Diabetes
Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs)
This study is a multi-country, multi-center retrospective observational cohort study based on secondary data collected via chart review, with the aim of describing patient characteristics (including relevant comorbidities)…
- Trial name
- NCT07457580
- Testing
- Teplizumab
- Where
- 14 sites in Belgium, France and 4 more
- Volunteers
- 60 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 1
A Trial Comparing the Effect of Exercise on Blood Glucose in Subjects With Type 1 Diabetes, Who Are Treated With Either Insulin Degludec or Insulin Glargine
This trial is conducted in Europe. The aim of the trial is to compare the effect of exercise on blood glucose in subjects with type 1 diabetes, who are treated with either insulin degludec (IDeg) or insulin glargine (IGlar).
- Trial name
- NCT01704417
- Testing
- insulin degludec, insulin glargine
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Non-inferiority Study to Compare the Efficacy and Safety of Mylan's Insulin Glargine With Lantus® in Type 1 Diabetes Mellitus Patients (INSTRIDE 1)
To test whether Mylan's insulin glargine once daily is non-inferior to Lantus® once daily (based on change in HbA1c from baseline to 24 weeks) when administered in combination with mealtime insulin lispro.
- Trial name
- INSTRIDE 1 (NCT02227862)
- Testing
- Mylan's insulin glargine, Lantus®
- Where
- 162 sites in United States, Canada and 9 more
- Volunteers
- 558 people
- Sponsor
- Mylan Inc.
Major Coronary Event, Cerebrovascular Accident
CARDS Is Designed To Show If Lowering Cholesterol With Atorvastatin In Type 2 Diabetics Without CV Disease Reduces The Risk Of CV Events
A study to assess the efficacy of once daily atorvastatin 10 mg versus placebo on cardiovascular endpoints in patients with non-insulin-dependent diabetes mellitus (NIDDM) who have a history of either hypertension, retinopathy…
- Conditions
- Major Coronary Event, Cerebrovascular Accident, Coronary Artery Bypass Graft, Angina, Unstable
- Trial name
- CARDS (NCT00327418)
- Testing
- Atorvastatin
- Where
- 135 sites in United Kingdom
- Volunteers
- 2,800 people
- Sponsor
- Pfizer
Type 1 Diabetes
A Performance Evaluation of the Enlite 3 Sensor
The purpose of this study is to support the use of the Enlite 3 sensor in arm and thigh in subjects age 14 - 75 years and provide additional characterization of the Enlite 3 sensor performance in arm in subjects age 14 - 75 years.
- Trial name
- NCT02649010
- Testing
- Enlite 3 Sensor
- Where
- 2 sites in United States
- Sponsor
- Medtronic MiniMed, Inc.
Type 2 Diabetes
Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes
The Revita® system is being investigated to assess the efficacy of DMR versus Sham on improvement in Glycemic, Hepatic and Cardiovascular endpoints for patients with Type 2 Diabetes who are inadequately controlled on one or more…
- Trial name
- REVITALIZE 1 (NCT04419779)
- Testing
- Duodenal Mucosal Resurfacing (DMR)
- Where
- 58 sites in United States, Belgium and 5 more
- Volunteers
- 320 people
- Sponsor
- Fractyl Health Inc.
Type 1 Diabetes
Feasibility Studies of Personalized Closed Loop
This is a single arm study comprised of a series of feasibility studies.
- Trial name
- NCT04203823
- Testing
- Cloud-based Digital Twin and Meal Prediction algorithms
- Where
- 12 sites in United States
- Volunteers
- 126 people
- Sponsor
- Medtronic MiniMed, Inc.
Type 1 Diabetes
To Evaluate the Bioavailability of a Tablet of AZD1656
To evaluate the bioavailability of a tablet of AZD1656.
- Trial name
- NCT00817505
- Testing
- AZD1656
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- AstraZeneca